Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Logan Easterday

Nurse Practitioner, Acute Care Franklin, TN Nurse Practitioner

NPI 1528635356 CMS profile 10603816

1909 Mallory Ln Ste 110, Franklin, TN 37067

Open in the dashboard

General payments

$7,448

309 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Logan Easterday of Franklin, TN is reported in the CMS Open Payments database as having received $7,448 across 309 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,289 45
2024 General $1,552 54
2023 General $1,920 83
2022 General $1,775 88
2021 General $912 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Logan Easterday
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Logan Easterday were reported at $1,289. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Logan Easterday Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $912 $123 $38–$327 $132
2022 $1,775 $130 $44–$369 $149
2023 $1,920 $144 $49–$410 $160
2024 $1,552 $146 $48–$433 $164
2025 $1,289 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $953 44 payments
  2. Janssen Biotech, Inc. $775 28 payments
  3. Pfizer Inc. $760 34 payments
  4. Myriad Genetic Laboratories, Inc. $529 18 payments
  5. Axonics Modulation Technologies, Inc. $403 15 payments
  6. Myovant Sciences Inc. $299 12 payments
  7. AbbVie, Inc. $292 12 payments
  8. Laborie Medical Technologies Corp. $271 7 payments
  9. Endo Pharmaceuticals Inc. $266 8 payments
  10. Urogen Pharma, Inc. $250 11 payments
  11. Other $2,649 120 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,301 307 payments
  2. Education $147 2 payments
Products named General payments · program years 2021–2025
  1. XTANDI $760 34 payments
  2. ORGOVYX Oncology $661 32 payments
  3. ORGOVYX Hormone Therapy $627 30 payments
  4. GEMTESA $564 24 payments
  5. Axonics $447 14 payments
  6. PROLARIS $417 13 payments
  7. ERLEADA $267 10 payments
  8. XIAFLEX $266 8 payments
  9. XYOSTED $235 12 payments
  10. BOTOX $228 9 payments
  11. Other $3,570 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,482

Median for Nurse Practitioner: 389

Drug cost

$315,925

Median for Nurse Practitioner: $21,885

Branded share of claims

33.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orgovyx Relugolix Brand 55 $136,496
Myrbetriq Mirabegron Brand 83 $88,393
Gemtesa Vibegron Brand 40 $33,939
Alfuzosin Hcl Er Alfuzosin Hcl Brand 483 $10,885
Solifenacin Succinate Generic 105 $8,998
Finasteride Generic 557 $8,512
Tamsulosin Hcl Generic 471 $8,048
Testosterone Cypionate Generic 155 $6,553
Testosterone Generic 31 $4,759
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 41 $1,776

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$71,454

Of which drugs: $3,102

Medicare patients

613

Average age 75

Services billed

1,940

115 women, 498 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 38%
Ischemic heart disease 37%
Diabetes 26%
Cancer 22%
Chronic kidney disease 18%
Atrial fibrillation 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $178
  • PFIZER INC. $41
$219 55 —
POSLUMA
  • Blue Earth Diagnostics Limited $111
$111 — —
XYOSTED
  • Antares Pharma, Inc. $99
$99 — —
JELMYTO
  • UROGEN PHARMA, INC. $63
$63 — —
Tlando
  • Verity Pharmaceuticals Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

309 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record